M
Myriam Labopin
Researcher at University of Paris
Publications - 586
Citations - 20011
Myriam Labopin is an academic researcher from University of Paris. The author has contributed to research in topics: Transplantation & Acute leukemia. The author has an hindex of 62, co-authored 503 publications receiving 15942 citations. Previous affiliations of Myriam Labopin include Pierre-and-Marie-Curie University & University of Florence.
Papers
More filters
Journal ArticleDOI
Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia
Vanderson Rocha,Myriam Labopin,Guillermo Sanz,William Arcese,Rainer Schwerdtfeger,Alberto Bosi,Niels Jacobsen,Tapani Ruutu,Marcos de Lima,Jürgen Finke,Francesco Frassoni,Eliane Gluckman +11 more
TL;DR: Cord blood from an unrelated donor is an alternative source of hematopoietic stem cells for adults with acute leukemia who lack an HLA-matched bone marrow donor.
Journal ArticleDOI
Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party
Christoph Schmid,Myriam Labopin,Arnon Nagler,Martin Bornhäuser,Jürgen Finke,Athanasios Fassas,Liisa Volin,Gunham Gurman,Johan Maertens,Pierre Bordigoni,Ernst Holler,Gerhard Ehninger,Emmanuelle Polge,Norbert Claude Gorin,Hans-Jochem Kolb,Vanderson Rocha +15 more
TL;DR: The results confirm that the clinical benefit of donor lymphocyte infusion in the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation (HSCT) is limited to a minority of patients.
Journal ArticleDOI
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).
M. Aoudjhane,Myriam Labopin,Norbert-Claude Gorin,A. Shimoni,T. Ruutu,H.-J. Kolb,Francesco Frassoni,J. M. Boiron,J. L. Yin,Jürgen Finke,H. Shouten,D. Blaise,M. Falda,A. A. Fauser,Jordi Esteve,Emmanuelle Polge,S. Slavin,D. Niederwieser,Arnon Nagler,Vanderson Rocha +19 more
TL;DR: Results of reduced intensity conditioning regimen (RIC) in the HLA identical haematopoietic stem cell transplantation (HSCT) setting have not been compared to those after myeloablative regimen HSCT in patients with acute myeloblastic leukaemia over 50 years of age, and these results may set the grounds for prospective trials comparing RIC with other strategies of treatment in elderly AML.
Journal ArticleDOI
A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions.
Aurélien Latouche,Aurélien Latouche,Arthur Allignol,Jan Beyersmann,Myriam Labopin,Jason P. Fine +5 more
TL;DR: It is argued that a complete understanding of the event dynamics requires that both hazards and cumulative incidence be analyzed side by side, and that this is generally the most rigorous scientific approach to analyzing competing risks data.
Journal ArticleDOI
Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases
Dominique Farge,Myriam Labopin,Alan Tyndall,Athanasios Fassas,Gianluigi Mancardi,Jaap Van Laar,Jian Ouyang,Tomas Kozak,John Moore,Ina Kötter,Virginie Chesnel,Alberto M. Marmont,Alois Gratwohl,Riccardo Saccardi +13 more
TL;DR: This largest cohort studied worldwide shows that autologous hematopoietic stem cell transplantation can induce sustained remissions for more than 5 years in patients with severe autoimmune diseases refractory to conventional therapy.